Abstracts | 41 diagnosis of PTSD. Finally, I will discuss aspects of the various trials that point to how NAC may be most effectively employed clinically in combination with psychosocial interventions, and perhaps other pharmacological treatments. 
Abstract
There has been a decline in new therapies for unipolar depression. Current pharmacological therapies are attributed to symptom remission in only 30% of individuals with unipolar depression. As such, there is a clear need for the development of new therapies, instigated by investigators rather than reliance on pharmaceutical companies.
There have been significant advancements in the understanding of the underlying pathophysiology of unipolar depression. Significant evidence is available to suggest that unipolar depression is mediated by inflammation. This is demonstrated by the induction of depressive symptoms following pro-inflammatory treatment (e.g. interferon in hepatitis-C) and more importantly, by alterations in peripheral cytokine levels in individuals with unipolar depression. Given this, we planned to trial a treatment specifically targeting inflammation as an adjunct to usual for individuals with moderate-severe unipolar depression. The agent selected is minocycline, a tetracycline antibiotic which has also been shown to inhibit microglial activation and also reduce oxidative stress, augment glutamate pathways and promote neuronal growth. This agent is of particular interest as in addition to increased inflammation, depression is also characterized by increased oxidative stress, altered glutamate function and decreased levels of neuronal growth factors (e.g. BDNF). We have completed a pilot double-blind placebo controlled trial of 200 mg/ day of minocycline as an adjunct to treatment as usual. The study includes 12 weeks of treatment followed by a followup visit 4 weeks later. The primary outcome measure for the study is the Montgomery Asberg Depression Rating Scale and a variety of clinical impression, functioning and quality of life scales are also included as secondary outcomes. The last study visit will be completed in December 2015 and trial results will be available in early 2016 to determine the preliminary efficacy of minocycline as an adjunctive therapy for moderate to severe unipolar depression.
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